- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00513214
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
September 30, 2011 updated by: XOMA (US) LLC
A Phase 1/2a, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D).
The study is a dose-escalation study designed to evaluate route of administration (intravenous or subcutaneous), doses, and dosing regimens for future studies.
Study Overview
Study Type
Interventional
Enrollment (Actual)
68
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Escondido, California, United States, 92026
-
-
Florida
-
Miami Gardens, Florida, United States, 33169
-
-
Nebraska
-
Omaha, Nebraska, United States, 68154
-
-
Texas
-
San Antonio, Texas, United States, 78229
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- American Diabetes Association (ADA) diagnostic criteria for T2D - Fasting blood glucose concentration ≥ 126 mg/dL (≥ 7.0 mmol/L) (must be measured within 35 days prior to Day 0) OR Symptoms of hyperglycemia (e.g., thirst, polyuria, weight loss, visual blurring) AND a casual/random plasma glucose value of ≥ 200 mg/dL (≥ 11.1 mmol/L) (must be measured within 35 days prior to Day 0)
- HbA1c ≥ 7.5% and ≤ 12% (DCCT standard)
- Current T2D of duration > 6 months at Screening
- T2D and other diseases must be stable. Stable disease is defined as disease that is judged stable by the investigator and which did not require a change in medications or dosing level on 4 or more consecutive days or 7 days in total within 35 days prior to Day 0.
- Age ≥ 18 and ≤ 70 at Screening
- Weight ≥ 80 lbs (36.3 kg) and ≤ 325 lbs (147.4 kg)
- BMI ≥ 23 and ≤ 40 kg/m2
- For female subjects of child-bearing age, a negative serum pregnancy test. For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study.
- Agree not to change diet and exercise regimen during the trial
Exclusion Criteria:
- Use of the following medications - Anti-inflammatory therapy other than aspirin ≤ 100 mg/day; Immunosuppressive treatment; Beta 2 and non-selective adrenergic blockers (Note: selective beta 1 blockers are permitted); Thiazolidinediones; Glucagon-like peptide (GLP) agonists including DPP4 inhibitors
- Change in medication for diabetes within 35 days prior to Day 0, defined as a change in dosing level on 4 or more consecutive days or 7 days in total
- Fasting C-peptide < 400 pM (< 1.20 μg/L)
- Hemoglobin < 8.0 g/dL, WBC < 3.0 X 103/mm3, platelet count < 125 X 103/mm3, creatinine > 1.5 mg/dL, AST/ALT > 2 X ULN, alkaline phosphatase > 2 X ULN
- Positive for GAD65 or IA-2 auto-antibodies
- Known HIV antibody, hepatitis B surface antigen, and/or hepatitis C antibody
- History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma
- Infectious disease - CRP > 30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening; History of recurrent infection or predisposition to infection; Active leg or foot ulcer
- Immunodeficiency
- Female subjects who are pregnant, planning to become pregnant during the course of the study, or breast-feeding
- History or symptoms of a demyelinating disease
- Clinically significant diabetic macular edema and/or proliferative diabetic retinopathy by history or fundoscopy
- Receipt of a live (attenuated) vaccine within 3 months prior to Screening
- Major surgery within 35 days prior to Day 0
- Participation in an investigational drug or device trial within 30 days prior to Screening
- Use of a therapeutic monoclonal antibody within 90 days prior to Screening
- Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to the study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Active Comparator: XOMA 052
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety assessed by pre- and post-treatment serial measurements of vital signs.
Time Frame: Part 1: Day 0 pre-treatment through Day 56. Part 2: Day 0 pre-treatment through Day 56. Part 3: Day 0 pre-treatment through Day 84.
|
Part 1: Day 0 pre-treatment through Day 56. Part 2: Day 0 pre-treatment through Day 56. Part 3: Day 0 pre-treatment through Day 84.
|
Safety assessed by treatment-emergent adverse events.
Time Frame: Part 1: Day 0 post-treatment through Day 56. Part 2: Day 0 post-treatment through Day 56. Part 3: Day 0 post-treatment through Day 84.
|
Part 1: Day 0 post-treatment through Day 56. Part 2: Day 0 post-treatment through Day 56. Part 3: Day 0 post-treatment through Day 84.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pedro Urquilla, MD, XOMA (US) LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
August 7, 2007
First Submitted That Met QC Criteria
August 7, 2007
First Posted (Estimate)
August 8, 2007
Study Record Updates
Last Update Posted (Estimate)
October 4, 2011
Last Update Submitted That Met QC Criteria
September 30, 2011
Last Verified
September 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- X052073
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on XOMA 052
-
National Institute of Arthritis and Musculoskeletal...WithdrawnBehcet's Disease | Muckle Wells Syndrome | AutoinflammatoryUnited States
-
XOMA (US) LLCSuspendedRheumatoid ArthritisUnited States
-
XOMA (US) LLCCompleted
-
University of ZurichXOMA (US) LLCCompletedDiabetes Mellitus Type 1Switzerland
-
XOMA (US) LLCCompletedType 2 Diabetes MellitusMexico
-
XOMA (US) LLCJuvenile Diabetes Research FoundationCompletedType 1 DiabetesSwitzerland
-
XOMA (US) LLCCompletedType 2 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
XOMA (US) LLCCompletedHypoglycemiaUnited States
-
SocraTec R&D GmbHSocraMetrics GmbH; Glatt Pharmaceutical Services GmbH & Co. KGCompletedComparative BioavailabilityGermany